Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Nature's Best: A Manual for Beautiful Train Rides - 2Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- 3Beating Wellbeing Difficulties: Individual Victories in Health
- 4'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- 5Italian authorities detain civilian rescue ship, German NGO says
- 'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna
- Auschwitz Committee wants German auction of Holocaust items scrapped
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- Two UN peacekeepers killed in explosion in Lebanon
- Tablets: Upgrade Your Understanding Experience
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- EU Commission slams Israel's death penalty law for Palestinians
- 3 Italian City Cars That Outsmarted Regulations and Rivals
